Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on December 22, 2022. The report details a corporate action approved by the Board of Directors on December 22, 2022, and announced via press release on December 23, 2022.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate governance event.
Material Changes
The primary material event reported is the approval of a 1-for-60 reverse stock split of the Company's outstanding and authorized shares of common stock. This action was taken pursuant to Section 607.10025 of the Florida Business Corporation Act.
- Split Ratio: 1-for-60
- Anticipated Effective Date: January 20, 2023
- Trading Resumption: January 23, 2023
- Trading Symbol: OGEN (remains unchanged)
- Exchange: NYSE American
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the procedural details of the stock split. The Company filed Articles of Amendment to its Amended and Restated Articles of Incorporation to effectuate this change.
Investor Verification Checklist
- Verify the exact effective date of the 1-for-60 reverse stock split (anticipated January 20, 2023).
- Confirm the resumption of trading on a split-adjusted basis on January 23, 2023.
- Review the attached Press Release (Exhibit 99.1) for additional details on the rationale for the split.
- Check subsequent filings to confirm the filing of the Articles of Amendment with the State of Florida.